Seer, Inc. (NASDAQ:SEER) CEO Sells $18,072.32 in Stock

Seer, Inc. (NASDAQ:SEER) CEO Omid Farokhzad sold 8,068 shares of Seer stock in a transaction dated Tuesday, February 4th. The shares were sold at an average price of $2.24, for a total value of $18,072.32. Following the completion of the sale, the chief executive officer now owns 1,428,217 shares of the company’s stock, valued at $3,199,206.08. The trade was a 0.56 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link.

Seer Price Performance

NASDAQ SEER opened at $2.26 on Friday. The company’s 50-day simple moving average is $2.36 and its two-hundred day simple moving average is $2.07. Seer, Inc. has a one year low of $1.51 and a one year high of $2.63.

Hedge Funds Weigh In On Seer

Several institutional investors have recently bought and sold shares of the business. AQR Capital Management LLC purchased a new position in shares of Seer in the 2nd quarter valued at $30,000. Cubist Systematic Strategies LLC purchased a new position in Seer in the second quarter valued at about $133,000. Palumbo Wealth Management LLC raised its holdings in Seer by 15.1% in the third quarter. Palumbo Wealth Management LLC now owns 122,292 shares of the company’s stock worth $241,000 after purchasing an additional 16,001 shares in the last quarter. GSA Capital Partners LLP lifted its position in shares of Seer by 194.9% during the third quarter. GSA Capital Partners LLP now owns 127,868 shares of the company’s stock valued at $252,000 after buying an additional 84,515 shares during the last quarter. Finally, Quadrature Capital Ltd boosted its holdings in shares of Seer by 301.7% in the 3rd quarter. Quadrature Capital Ltd now owns 57,088 shares of the company’s stock valued at $112,000 after buying an additional 42,875 shares in the last quarter. 75.20% of the stock is owned by hedge funds and other institutional investors.

About Seer

Seer, Inc, a life sciences company, engages in developing and commercializing products to decode the biology of the proteome. It develops Proteograph Product Suite, an integrated solution that includes proprietary engineered nanoparticles, consumables, automation instrumentation, and software to perform proteomic analysis to provide a solution that can be incorporated by nearly any lab for research use only.